Gujarat Kidney IPO
Gujarat Kidney IPO
Gujarat Kidney and Super Speciality Limited (GKASSL), incorporated in 2019, is a regional healthcare provider in central Gujarat specializing in renal sciences and multi-speciality tertiary care. The company operates 7 hospitals and 4 pharmacies across Vadodara, Godhra, Bharuch, Borsad, and Anand, with an operational capacity of 340 beds. It focuses on high-end surgical procedures, including kidney transplants and robotic-assisted surgeries. GKASSL follows an asset-light 'roll-up' strategy, expanding rapidly through the acquisition and integration of existing medical facilities in underserved Tier-II and Tier-III markets.
Investment Timeline
🤖 Smart Analysis
*AI score is algorithmic and for educational purposes only.
🎯 Application Strategy
Action: ⛔ AVOID - Better opportunities available elsewhere
Lots: NOT RECOMMENDED
⏳ Timing Advice
⏰ Apply by DAY 2 NOON - High demand, good allotment still possible
Key Factor Analysis
Issue Details
Object of the Issue
The company proposes to utilize the Net Proceeds from the Issue towards the following objects:
- Proposed acquisition of Parekhs Hospital at Ahmedabad (₹77.00 Cr).
- Funding capital expenditure for setting up a new hospital in Vadodara (₹30.10 Cr).
- Part-payment for the already acquired Ashwini Medical Centre (₹12.40 Cr).
- Acquisition of additional shareholding in the subsidiary Harmony Medicare (₹10.78 Cr).
- Purchase of robotic equipment (MAKO SmartRobotics™) for the Vadodara facility (₹6.83 Cr).
- Full or part repayment of certain secured borrowings (₹1.20 Cr).
- General Corporate Purposes and inorganic growth.
Frequently Asked Questions
What is the current GMP of Gujarat Kidney IPO?
What is the AI Prediction for Gujarat Kidney IPO?
When will the allotment for Gujarat Kidney IPO be announced?
What is the listing date for Gujarat Kidney IPO?
Liability Disclaimer: Ipofly.com is an informational platform. We are not SEBI registered. The information provided here (including GMP and AI analysis) is for educational purposes only and should not be considered financial advice. Investments in the stock market are subject to market risks. Please consult your financial advisor before investing.